16665-38-6

Basic information

• Product Name: (4-METHOXY-PYRIDIN-2-YL)-METHANOL
• Synonyms: CHEMPACIFIC 38146;(4-METHOXY-PYRIDIN-2-YL)-METHANOL;Zinc04352699;4-Methoxy-2-PyridineMethanol;4-METHOXY-2-HYDROXYMETHYLPYRIDINE;2-(Hydroxymethyl)-4-methoxypyridine
• CAS NO: 16665-38-6
• Molecular Formula: C₇H₉NO₂
• Molecular Weight: 139.15
• Mol File: 16665-38-6.mol
• Article Data: 30

Chemical Properties

• Melting Point: 69-70°C
• Boiling Point: 125-130℃ (3 Torr)
• Flash Point: 112.036 °C
• Appearance: /
• Density: 1.155 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 13.22±0.10(Predicted)
• CAS DataBase Reference: (4-METHOXY-PYRIDIN-2-YL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHOXY-PYRIDIN-2-YL)-METHANOL(16665-38-6)
• EPA Substance Registry System: (4-METHOXY-PYRIDIN-2-YL)-METHANOL(16665-38-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 16665-38-6(Hazardous Substances Data)

Usage

General Description

(4-Methoxy-pyridin-2-yl)-methanol, also known as 4-methoxy-2-pyridylmethanol, is a chemical compound with the molecular formula C7H9NO2. It is a white to off-white crystalline powder that is commonly used in the pharmaceutical and agrochemical industries. (4-METHOXY-PYRIDIN-2-YL)-METHANOL has various applications, including as an intermediate in the synthesis of pharmaceuticals and as a starting material for the production of crop protection agents. It is also known to have potential biological activity, making it a subject of interest for medicinal and chemical research. However, further studies on its properties, uses, and potential risks are necessary to fully understand its impact on human health and the environment.

Upstream product

• 6890-60-4 4-methoxy-2-methylpyridine 1-oxide 
• 67-56-1 methanol 
• 63071-10-3 (4-chloropyridin-2-yl)methanol 
• 124-41-4 sodium methylate 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 
• 24103-75-1 4-methoxy-2-methylpyridine 
• 98-98-6 2-Picolinic acid 
• 109-06-8 α-picoline 
• 1476067-43-2 C₉H₈F₃NO₃ 
• 98197-88-7 4-nitro-2-(hydroxymethyl)pyridine 
• 29681-43-4 methyl 4-methoxypicolinate 
• 1122-96-9 4-methoxypyridine N-oxide 
• 420-37-1 trimethoxonium tetrafluoroborate 
• 87838-46-8 C₁₄H₁₅N₃O₃S 

Downstream Products

• 16744-81-3 4-methoxypyridine-2-carbaldehyde 
• 99651-28-2 2-chloromethyl-4-methoxypyridine 
• 62734-08-1 2-Chloromethyl-4-methoxypyridine hydrochloride 
• 122307-84-0 2-(4-Methoxy-pyridin-2-ylmethylsulfanyl)-6-phenyl-3H-thieno[3,4-d]imidazole 
• 122320-37-0 2-(4-Methoxy-pyridin-2-ylmethanesulfinyl)-6-phenyl-3H-thieno[3,4-d]imidazole 
• 122307-87-3 6-(4-Methoxy-phenyl)-2-(4-methoxy-pyridin-2-ylmethylsulfanyl)-3H-thieno[3,4-d]imidazole 
• 122307-95-3 6-(4-Methoxy-phenyl)-2-(4-methoxy-pyridin-2-ylmethanesulfinyl)-3H-thieno[3,4-d]imidazole 
• 108337-96-8 4-Methoxy-2',6'-dimethyl-1',4'-dihydro-[2,4']bipyridinyl-3',5'-dicarboxylic acid 5'-[2-(benzyl-methyl-amino)-ethyl] ester 3'-methyl ester 

Relevant articles and documents

Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors

To validate the hypothesis that Tyr748 is a crucial residue to aid the discovery of highly selective phosphodiesterase 8A (PDE8A) inhibitors, we identified a series of 2-chloroadenine derivatives based on the hit clofarabine. Structure-based design targeting Tyr748 in PDE8 resulted in the lead compound 3a (IC50 = 0.010 μM) with high selectivity with a reasonable druglike profile. In the X-ray crystal structure, 3a bound to PDE8A with a different mode from 3-isobutyl-1-methylxanthine (a pan-PDE inhibitor) and gave a H-bond of 2.7 ? with Tyr748, which possibly interprets the 220-fold selectivity of 3a against PDE2A. Additionally, oral administration of compound 3a achieved remarkable therapeutic effects against vascular dementia (VaD), indicating that PDE8 inhibitors could serve as potential anti-VaD agents.

Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity

Cruzain, an essential cysteine protease of the parasitic protozoan, Trypanosoma cruzi, is an important drug target for Chagas disease. We describe here a new series of reversible but time-dependent inhibitors of cruzain, composed of a dipeptide scaffold appended to vinyl heterocycles meant to provide replacements for the irreversible reactive "warheads" of vinyl sulfone inactivators of cruzain. Peptidomimetic vinyl heterocyclic inhibitors (PVHIs) containing Cbz-Phe-Phe/homoPhe scaffolds with vinyl-2-pyrimidine, vinyl-2-pyridine, and vinyl-2-(N-methyl)-pyridine groups conferred reversible, time-dependent inhibition of cruzain (Ki? = 0.1-0.4 μM). These cruzain inhibitors exhibited moderate to excellent selectivity versus human cathepsins B, L, and S and showed no apparent toxicity to human cells but were effective in cell cultures of Trypanosoma brucei brucei (EC50 = 1-15 μM) and eliminated T. cruzi in infected murine cardiomyoblasts (EC50 = 5-8 μM). PVHIs represent a new class of cruzain inhibitors that could progress to viable candidate compounds to treat Chagas disease and human sleeping sickness.

Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation

Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe